Progress in understanding the pathogenesis of nonalcoholic fatty liver-disease

Hepatology

Volumn 41, Issue 1, 2005, Pages 204-

  Moseley, Richard H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY LIVER; HUMAN; INSULIN RESISTANCE; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; NOTE; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL;

EID: 11244349748     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20558     Document Type: Note

References (25)

1. Clark JM, Biancati FL, Diehl AM, The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterology 2003;98:960-967.
2. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-1123.
3. Day CP, James O. Steatohepatitis:a tale of two 'hits'? Gastroenterology 1998;114:842-845.
4. Koteish A, Diehl AM. Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol 2002;16:679-690.
5. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002;37:206-213.
6. Ghoshal AK, Ahluwalia M, Farber E. The rapid induction of liver cell death in rats fed a choline-deficient methionine-low diet. Amer J Pathol 1983;113:309-314.
7. Sahai A, Malladi P, Melin-Aldana H, Green RM, Whitington PF. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol 2004;287: G264-G273.
8. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin - a molecule for all seasons. QJM 2002;95:3-13
9. Sodhi CP, Phadke SA, Batlle D, Sahai A. Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin. Am J Physiol 2001;280:F667-F674.
10. Kawashima R, Mochida S, Matsui A, YouLuTuZ Y, Ishikawa K, Toshima K, et al. Expression of osteopontin in Kupffer cells and hepatic macrophages and stellate cells in rat liver after carbon tetrachloride intoxication: a possible factor for macrophage migration into hepatic necrotic areas. Biochem Biophys Res Commun 1999;256:527-531.
11. Harada K, Ozaki S, Sudo Y, Tsuneyama K, Ohta H, Nakanuma Y. Osteopontin is involved in the formation of epithelioid granuloma and bile duct injury in primary biliary cirrhosis. Pathol Int 2003;53:8-17.
12. Matsui A, Mochida S, Ohno A, Nagoshi S, Hirose T, Fujiwara K. Plasma osteopontin levels in patients with fulminant hepatitis. Hepatol Res 2004;29:202-206.
13. Berman JS, Serlin D, Li X, Whitley G, Hayes J, Rishikof DC, et al. Altered bleomycin-induced lung fibrosis in osteopontin-deficient mice Am J Physiol 2004;286:L1311-L1318.
14. Matsui Y, Jia N, Okamoto H, Kon S, Onozuka H, Akino M, et al. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 2004;43:1195-1201.
15. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 2002;52:19-24.
16. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055-1061.
17. Stiles B, Groszer M, Wang S, Jiao J, Wu H. PTENless means more. Develop Biol 2004;273:175-184.
18. Hu, T-H, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 2003;97:1929-1940.
19. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. HEPATOLOGY 2002;35:1485-1493.
20. Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim Y-J, et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity. Proc Natl Acad Sci U S A 2004;101:2082-2087.
21. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004;113:1774-1783.
22. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:575-594.
23. Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 2004;40:47-51.
24. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. HEPATOLOGY 2004;39:1286-1296.
25. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-2963.